Report The Panel agreed on the outline of the 2027 IPCC Methodology Report on Carbon Dioxide Removal Technologies, Carbon Capture, Utilization, and Storage for National Greenhouse Gas Inventories (Additional guidance) at its 63rd Session held in Lima, Peru from 27-30 October 2025 (Decision IPCC-LXIII-6). The report will be a single Methodology Report comprising an Overview Chapter and six volumes consistent with the format of the 2006 IPCC Guidelines for National Greenhouse Gas Inventories. The structure of the Methodology Report is consistent with the 2006 IPCC Guidelines so as to make it easier for inventory compilers to use this Methodology Report with the 2006 IPCC Guidelines. Topics that will be addressed include: Transport, injection and sequestering of CO2 in relation to enhanced oil, gas, and coal-bed methane recovery Production of products containing or derived from captured and/or removed CO2 Carbonation of cement and lime-based structures Soil carbon sinks and related emissions enhanced through biochar and weathering and other elements Coastal wetlands carbon dioxide removal types not in previous IPCC Guidelines as well as additional information on mangroves, tidal marshes and seagrass in coastal waters Durable biomass products Carbon dioxide capture from combustion and process gases Direct air capture Carbon dioxide utilisation Carbon dioxide transport including cross border issues Carbon dioxide injection and storage CO2 removal through direct capture of CO2 from water already processed by inland and coastal facilities; and related elements across the range of categories of the IPCC Guidelines. The national greenhouse gas inventory includes sources and sinks occurring within the territory over which a country has jurisdiction. Over 150 experts are expected to participate in the writing process, which will be completed by 2027. The participants will be selected by the Task Force Bureau taking into account scientific and technical expertise, geographical and gender balance to the extent possible in line with Appendix A to the Principles Governing IPCC Work. The First Lead Authors’ meeting will be held in Rome, Italy, in April 2026. Preparatory Work The decision by the Panel to prepare this Methodology Report was informed by the work of experts at the scoping meeting held in Copenhagen, Denmark, from 14-16 October 2024. Prior to the scoping meeting, an expert meeting was held at Vienna, Austria 1-3 July 2024. These meetings considered Carbon Dioxide Removal (CDR) methods mentioned in the AR6 WGIII Report as a starting point for discussion and noted that several CDR activities have been already covered by the existing IPCC Guidelines. More Information The IPCC Secretary has written to national government focal points inviting nominations of authors by 12 December 2025.

Fast Facts Medicaid programs that cover prescription drugs are generally required to cover drugs that are (1) FDA approved and (2) made by a manufacturer that participates in the Medicaid Drug Rebate Program. 13 Medicaid programs didn’t cover Mifeprex and its generic equivalent, Mifepristone Tablets, 200 mg, when required. These drugs are used for medical abortion. We recommended the Centers for Medicare & Medicaid Services ensure Medicaid programs comply with federal requirements for covering Mifepristone Tablets, 200 mg. We also reiterated our 2019 recommendation on Mifeprex, which hasn’t been implemented. White pills spilling from a pill bottle. Skip to Highlights Highlights What GAO Found Medicaid programs that choose to cover outpatient prescription drugs are required to cover all Food and Drug Administration (FDA) approved drugs for their medically accepted indications when those drugs are made by a manufacturer that participates in the Medicaid Drug Rebate Program (MDRP), except as outlined in federal law. The FDA has approved two drugs—Mifeprex in 2000 and its generic equivalent in 2019, referred to as Mifepristone Tablets, 200 mg—for the medical termination of an intrauterine pregnancy, known as a medical abortion. Danco Laboratories and GenBioPro are the exclusive manufacturers of Mifeprex and Mifepristone Tablets, 200 mg, respectively, and both manufacturers participate in the MDRP. Medicaid programs in all 50 states, the District of Columbia, and Puerto Rico cover prescription drugs and participate in the MDRP. According to officials from the Centers for Medicare & Medicaid Services (CMS)—the federal agency within the Department of Health and Human Services (HHS) responsible for ensuring Medicaid programs’ compliance—none of the MDRP’s statutory exceptions apply to Mifeprex or Mifepristone Tablets, 200 mg. Thus, these 52 Medicaid programs must cover these drugs when prescribed for medical abortion in circumstances eligible for federal funding, such as when the pregnancy is the result of rape or incest. GAO identified gaps in Medicaid programs’ coverage of Mifeprex and Mifepristone Tablets, 200 mg. Officials from 35 of the 49 programs who responded to GAO questions said their programs covered Mifeprex and Mifepristone Tablets, 200 mg for medical abortion, as of December 31, 2024. In contrast, officials from 13 programs told GAO their programs did not cover either drug for medical abortion. An official from the remaining program did not specify the medical indications for which its program covered the drugs. Medicaid Programs’ Coverage of Danco Laboratories’ Mifeprex and GenBioPro’s Mifepristone Tablets, 200 mg, as of December 31, 2024 Note: For more details, see fig. 1 in GAO-25-107911. State officials’ responses to GAO’s questions indicated that some states may not be complying with the MDRP requirements for covering Mifeprex and Mifepristone Tablets, 200 mg. However, CMS has not determined the extent to which states comply with the MDRP requirements for these drugs. CMS officials told GAO they were not aware of the following: Nine programs did not cover Mifeprex and Mifepristone Tablets, 200 mg for any medical indication, as of December 31, 2024; GAO reported four of these programs did not cover Mifeprex in 2019. Mifepristone Tablets, 200 mg was not available at the time of GAO’s 2019 report. Four additional Medicaid programs did not cover either drug when prescribed for medical abortion, as of December 31, 2024. CMS was not aware of these coverage gaps, in part, because it had not implemented GAO’s 2019 recommendation to take actions to ensure Medicaid programs comply with MDRP requirements to cover Mifeprex. CMS also has not taken actions related to the coverage of Mifepristone Tablets, 200 mg, as of August 2025. Without such actions, CMS lacks assurance that Medicaid programs comply with MDRP requirements and Medicaid beneficiaries may lack access to these drugs when appropriate. Why GAO Did This Study GAO was asked to describe Medicaid programs’ coverage of mifepristone. This report examines Medicaid programs’ coverage of Mifeprex and Mifepristone Tablets, 200 mg, among other things. GAO reviewed laws and CMS guidance on the MDRP, and coverage of Mifeprex and Mifepristone Tablets, 200 mg. GAO also sent written questions to officials from the 52 Medicaid programs that participate in the MDRP regarding their coverage of these drugs, and reviewed officials’ responses from the 49 programs that provided GAO information. Recommendations GAO reiterates its 2019 recommendation that CMS take actions to ensure states’ compliance with MDRP requirements to cover Mifeprex. GAO also recommends that CMS determine the extent to which states comply with federal Medicaid requirements regarding coverage of GenBioPro’s Mifepristone Tablets, 200 mg, and take actions, as appropriate, to ensure compliance. In response to the recommendation, HHS noted it is reviewing applicable law and will determine the best course of action to address it moving forward. Recommendations for Executive Action Agency Affected Recommendation Status Centers for Medicare & Medicaid Services The Administrator of CMS should determine the extent to which states comply with federal Medicaid requirements regarding coverage of GenBioPro's Mifepristone Tablets, 200 mg, and take actions, as appropriate, to ensure compliance. (Recommendation 1) Open Actions to satisfy the intent of the recommendation have not been taken or are being planned. When we confirm what actions the agency has taken in response to this recommendation, we will provide updated information. Full Report Full Report (11 pages)

05.12.2025 – The European Scientific Advisory Board on Climate Change, established under the European Climate Law, will continue to be supported in its second term (2026-2030) by Ottmar Edenhofer. The Director of the Potsdam Institute for Climate Impact Research (PIK) has now been appointed by the Management Board of the European Environment Agency in Copenhagen for another four-year term on the Advisory Board, beginning on 24 March 2026. Advising EU policymakers on the path to the declared goal of climate neutrality: PIK Director Ottmar Edenhofer. Photo: PIK/Karkow The Advisory Board gives independent advice and produces reports on EU policies, and their coherence with the Climate Law and the EU’s commitments under the Paris Agreement. It consists of 15 high-level scientific experts covering a wide range of relevant fields. Edenhofer is serving as the Advisory Board’s current Chair during its first term (2022-2026). Highlights during this period have included scientific recommendations for an ambitious EU climate target for 2040, an analysis of the action needed to achieve climate neutrality, and a study on scaling up atmospheric carbon removals. “I am very thankful for the great opportunity to continue supporting EU climate policy in this service role for the next four years,” says Edenhofer, who is also Professor for The Economics and Politics of Climate Change at the Technische Universität Berlin. “The European Union has taken some important steps in recent years towards its declared goal of climate neutrality by 2050. It remains important to make climate policy cost-effective, socially balanced and consistent with the requirements of an internationally competitive economy. As a member of the Advisory Board, I will do my best to provide scientific advice to policymakers on this task.” The composition of the Advisory Board for the next four-year term has now been decided through an open, fair and transparent selection process lasting several months. The decision on who will chair the body in future is not expected until beginning of the second term. The other members of the Advisory Board in the second term are: • Annela Anger-Kraavi – University of Cambridge • Constantinos Cartalis – National and Kapodistrian University of Athens • Suraje Dessai – University of Leeds’ School of Earth, Environment, and Sustainability • Laura Díaz Anadón – University of Cambridge • Vera Eory – Scotland’s Rural College • Lena Kitzing - Technical University of Denmark • Kati Kulovesi – University of Eastern Finland • Lars J. Nilsson – Lund University • Åsa Persson – KTH Royal Institute of Technology’s Climate Action Centre • Keywan Riahi – International Institute for Applied Systems Analysis • Jean-François Soussana – French National Research Institute for Agriculture, Food and the Environment • Giorgio Vacchiano – University of Milan • Detlef van Vuuren – PBL Netherlands Environmental Assessment Agency • Zinta Zommers – University of Toronto

Abstract RNA polymerase III (Pol III) transcribes cytosolic transfer RNAs (tRNAs) and other non-coding RNAs (ncRNAs) essential to cellular function. However, many aspects of Pol III transcription and processing, including RNA modifications, remain poorly understood, mainly due to a lack of available sensitive and systematic methods for their analysis. Here, we present DRAP3R (Direct Read and Analysis of Polymerase III transcribed RNAs), a modified nanopore direct RNA sequencing approach and analysis framework that enables the specific and sensitive capture of pre-mature Pol III transcribed RNAs. Applying DRAP3R to distinct cell types, we identify previously unconfirmed tRNA genes and other novel Pol III transcribed RNAs, thus expanding the known Pol III transcriptome. Critically, DRAP3R also enables discrimination between co- and post-transcriptional RNA modifications such as pseudouridine (Ψ) and N6-methyladenosine (m6A) at single-nucleotide resolution across all examined transcript types and reveals differential Ψ installation patterns across tRNA isodecoders and other ncRNAs. Finally, applying DRAP3R to epithelial cells infected with Herpes Simplex Virus Type 1 reveals an extensive remodelling of both the Pol III transcriptome and epitranscriptome. Our findings thus establish DRAP3R as a powerful tool for systematically studying Pol III transcribed RNAs and their modifications in diverse cellular contexts.

Abstract Strike-slip restraining bends, such as the Levant Fault, belonging to push-up systems and the Jamaican fault network, belonging to duplex systems, display a diversity of fault geometries and deformation patterns that reflect distinct modes of lithospheric-scale strain localization. To investigate the origin of this variability, we develop 3D numerical models of transpressional strike-slip systems using heterogeneous simple shear boundary conditions and thermally-dependent, non-linear rheology. Unlike classical analog or numerical models that impose velocity discontinuities, our approach allows spontaneous fault localization that naturally generates transpression. We systematically explore how the position and geometry of inherited weak zones influence fault development. We show that three distinct strike-slip systems emerge: (1) push-up systems with a single strike-slip fault and outward-propagating thrusts; (2) duplex systems with interacting parallel faults connected by P-shears; and (3) systems of non-interacting parallel faults. These results highlight spontaneous strike-slip localization and how initial heterogeneities control formation and evolution of long-term lithospheric deformation.

Abstract Whether a booster dose of hepatitis B vaccine is necessary for adolescents remains controversial. We conducted a retrospective cohort study from the Immunization Information System and The National Notifiable Disease Reporting System to evaluate the impact of hepatitis B virus (HBV) vaccination programs (universal infant hepatitis B immunization and adolescent booster) on HBV infection. The vaccine effectiveness (VE) of hepatitis B vaccine is 64.43% (95% CI 57.78% − 71.08%) within 10 years of birth, escalates to 95.36% (95% CI 94.84% − 95.88%) by 20 years, and decreases to 67.35% (95% CI 63.86% − 70.85%) by 30 years. Compared with Beijing’s birth-vaccinated-only group, the booster group showed a lower relative VE in the first 10 years but a slight increase thereafter. Compared with the national control group, the booster group maintained a relatively high relative VE with a smaller decline magnitude. This study demonstrates that adolescent HBV booster vaccination administered during junior high school improves hepatitis B surface antibody levels and contributes to a further reduction in the incidence of HBV infection.

Abstract Lattice strain critically affects electrochemical performance and durability of battery electrode materials. Here we report an electron-backscatter-diffraction-based imaging method to quantify lattice strain evolution and its spatial heterogeneity in two technologically important layered oxide cathodes (i.e. positive electrodes). Quantitative analysis is achieved by examining numerical distribution of the crystal misorientation data from thousands of positive electrode particles, which follows a positively skewed distribution. We reveal pronounced lattice strain heterogeneities both within individual grains and across different particles. These strain variations self-heal during relithiation but intensify with deeper delithiation and repeated cycling. The increased strain impedes Li-ion bulk diffusion, thereby limiting the maximum accessible capacity, especially at high current densities. Three-dimensional pole-figure analysis further identifies layer bending and layer twisting as the two major lattice distortion modes in the electrochemically cycled positive electrode particles. The accumulation of the unrecoverable layer bending governs the kinetically controlled capacity loss in the layered oxide positive electrodes.

Abstract Despite substantial recent declines, general population HIV incidence in sub-Saharan Africa remains above international targets. Better description of risk factors for new infections would improve prioritisation of interventions. Using data from population-based cohorts in Kenya, Malawi, Tanzania, South Africa, Uganda, Zimbabwe we described the prevalence of risk factors for men and women aged 15-24 and 25-49 and estimated the association between individual and community-level risk factors and HIV acquisition between 2005 and 2016. Among 43,434 men and 55,919 women aged 15 to 49 there were 4,612 seroconversions. Education, marital status, male circumcision, new sexual partners, types of partner, prevalence of untreated HIV infection in the community and community partner acquisition rates were associated with HIV incidence. Only the prevalence of untreated HIV was a risk for both sexes and apparent at all ages. The prevalence of risk factors varied by age, sex and study. HIV incidence was higher in people aged 25-49 living in communities where men had high partner acquisition rates. Our results show potential for improved prevention through changed timing of prevention interventions relative to behaviour and the utility of using community characteristics to target prevention.